Logic was along the lines that we don’t yet have approval to run a modern clinical trial in Breast Cancer. It’s been trialed historically in hundreds of patients in breast cancer, some were Phase III trials. Now we have modern preclinical data that shows Bisantrene works in Breast Cancer.
Once we have approval to start a Breast Cancer trial, I will raise probability of the Breast Cancer indication.
Bisantrene was previously approved for AML, had strong historic results and we had recent Israel trial. Hence the higher probability for AML.
Bisantrene has never been trial in humans for FTO, but we have strong safety data. Will lift probability after race have their own preclinical data and again when a trial is approved.
RAC Price at posting:
$1.72 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)